Poster Abstract Session:
156. HIV: Antiretroviral Therapy
Friday, October 6, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD

Tracks: HIV-STD-TB, Global ID, Adult ID


Presentations:
A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
Paul Sax, MD; Edwin Dejesus, MD; Gordon Crofoot, MD; Douglas Ward, MD; Paul Benson, MD; Lilian Wei, PhD; Kirsten White, PhD; Sean Collins, MD; Hal Martin, MD, MPH; Andrew Cheng, MD PhD; Erin Quirk, MD
No Emergent Resistance in HIV-1 Infected Virologically-Suppressed Subjects Who Switched to R/F/TAF
Danielle Porter, Ph.D.; Rima Kulkarni, BS; Huyen Cao, MD; Devi Sengupta, MD; Kirsten White, PhD
Sword 1 & 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender
Sharon Walmsley, MD, FRCP; Gary Richmond, MD; Fritz Bredeek, MD, PhD, FACP; Moti Ramgopal, MD, FACP, FIDSA; Chien-Ching Hung, MD, MIH, PhD; Elizabeth Blair, PharmD; Lesley Kahl, PhD; Mark Underwood, PhD; Kostas Angelis, PhD; Kati Vandermeulen, BSc; Brian Wynne, MD; Michael Aboud, MD
Efficacy and Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 96: Subgroup Analysis of a Randomized Switch Study
Jason A Flamm, MD; Thanes Vanig, MD; Joseph Gathe, MD; Clifford Kinder, MD; Michael Para, MD, FIDSA; Bruce Rashbaum, MD; Sorana Segal-Maurer, MD; David Shamblaw, MD; Michael Wohlfeiler, JD, MD; Benjamin Young, MD, PhD; Christine Zurawski, MD, FACP; Martin S Rhee, MD
High Tenofovir Failure Rates in an Emerging, Non-B Subtype HIV Epidemic
Edsel Maurice Salvana, MD, DTM&H, FIDSA; Brian Schwem, PhD; Genesis Samonte, MD; Elizabeth Telan, MD; Rosario Tactacan-Abrenica, MD; Patrick Ching, MD; Kevin Mendoza, RN; Geraldine Arevalo, BS; Marissa Alejandria, MD, MSc; Katerina Leyritana, MD; Lyka Trinidad, RN; Christine Penalosa, MD; Jodor Lim, MD, FPCP, FPSMID
Posters
  • Salvana TDF Poster 1385.pdf (521.7 kB)
  • Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)
    Joseph Custodio, PhD; Steve West, MSPH; Amanda Yu, BSc; Hal Martin, MD, MPH; Hiba Graham, Pharm D; Erin Quirk, MD; Brian Kearney, Pharm D
    Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
    Jafar Sadik Shaik, PhD; Susan Ford, PharmD; Yu Lou, MS; Zhiping Zhang, PhD; Kalpana Bakshi, MS; Allan Tenorio, MD; Christine Trezza, PharmD; William Spreen, PharmD; Parul Patel, PharmD
    Posters
  • IDWeek 2017_Shaik et al.pdf (232.7 kB)
  • Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
    Ridhi Parasrampuria, PhD; Susan Ford, PharmD; Yu Lou, MS; Caifeng Fu, MS; Kalpana Bakshi, MS; Allan Tenorio, MD; Christine Trezza, PharmD; William Spreen, PharmD; Parul Patel, PharmD
    Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
    Heather Sevinsky, MS; Mindy Magee, RPh, PharmD; Peter Ackerman, MD; Robert Adamczyk, PharmD; Jennifer Karkas, BS; Susan Lubin, RN, MA; Palanikumar Ravindran, PhD; Cyril Llamoso, MD; Timothy Eley, PhD; Katy Moore, RPh, PharmD
    Patient Experience & Views on Antiretroviral Treatment - Findings from the Positive Perspectives Survey
    Benjamin Young, MD PhD; Bruno Spire, MD PHD; Diego Garcia Morcillo, MA; Marvelous Muchenje, BSW, RSW; Kneeshe Parkinson, AAS; Moritz Krehl, BA; Simone Marcotullio, BSc; Brent Allan, Msc; Yogesh Punekar, PHD; Angelina Namiba, BA Hons; Annemiek deRuiter, MBBS, FRCP; Sophie Barthel, PHD; Justin Koteff, PharmD; Cindy Garris, MS; Christopher Nguyen, MD; Andrew Ustianowski, MBBS, MRCP, DTM&H, PCME, PhD, FRCP; Pedro Eitz Ferrer, BSc MPH PHD; Andrew Murungi, MPharm
    The Safety of Substitution of Antiretroviral Regimen in Non-Clinical Trial Settings in Asian Countries
    In Young Jung, MD; David Boettiger, PhD; Wingwai Wong, MD; Man Po Lee, MD; Sasisopin Kiertiburanakul, MD, MHS; Romanee Chaiwarith, MD; Anchalee Avihingsanon, MD, PhD; Junko Tanuma, MD; N. Kumarasamy, M.B.B.S., PhD; Adeeba Kamarulzaman, MD; Fujie Zhang, MD; Pacharee Kantipong, MD; Oon Tek Ng, MBBS(Singapore), MRCP(UK), FAMS, MPH; Benedict Lh Sim, MD; Matthew Law, MD; Jeremy Ross, MD; Jun Yong Choi, MD, PhD
    Gender Differences in Virologic Response after Antiretroviral Therapy in Treatment-naïve HIV-infected Individuals: Results from the 550 Clinic HIV Cohort Study.
    Andrea Reyes Vega, MD; Alejandra Loban, MD; Kavitha Srinivasan, MD; Stephen Furmanek, MS MPH; Connor English, BS; Mary Bishop, RPH; Cathy Spencer, PharmD; Daniel Truelove, PharmD; Julio Ramirez, MD; Anupama Raghuram, MD; Paula Peyrani, MD
    Posters
  • Gender ID WEEK 2017 FINAL.pdf (473.9 kB)
  • WEIGHT GAIN AFTER SWITCH FROM EFAVIRENZ-BASED TO INTEGRASE INHIBITOR-BASED REGIMENS
    Jamison Norwood, MD; Megan Turner, M.A.; Carmen Bofill, M.P.H.; Cathy Jenkins, M.S.; Sally Bebawy, B.S.; Peter Rebeiro, Ph.D., M.H.S.; Todd Hulgan, MD, MPH, FIDSA; Stephen Raffanti, MD, MPH, FIDSA; David Haas, MD, FIDSA; Timothy R. Sterling, MD, FIDSA; John Koethe, MD
    Posters
  • IDSA Poster 9.27.2017.pdf (343.3 kB)
  • Application of The Change Point Analysis to The Long-Term Restoration of CD4 Count Among Well-Controlled HIV-1 Infected Patients Who Started Antiretroviral Therapy
    Mutoh Yoshikazu, MD; Takeshi Nishijima, MD. PhD; Noriko Tanaka, PhD; Yosuke Inaba, MSc; Yoshimi Kikuchi, MD, PhD; Hiroyuki Gatanaga, MD, PhD; Shinichi Oka, MD, PhD
    Posters
  • poster 2017IDwek 1399.pdf (1.5 MB)
  • Treatment of HIV and Use of HAART in HIV Infected Patients with Acute Septic Shock
    Christopher Polk, MD; Samuel Webb, MD; Nigel Rozario, MS; Charity Moore, PhD; Michael Leonard, MD
    Posters
  • Polk1400.pdf (734.1 kB)
  • A Prediction Model of Pre-treatment HIV RNA Levels in Naïve Thai HIV-infected Patients: An Application for Resource-limited Settings
    Nisha Pongpech, MD; Anchalee Avihingsanon, MD, PhD; Romanee Chaiwarith, MD, MHS; Pacharee Kantipong, MD; David Boettiger, PhD; Jeremy Ross, MD; Sasisopin Kiertiburanakul, MD, MHS
    Posters
  • posterIDWeek.pdf (643.2 kB)
  • CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.